- Lactic acidosis is a rare complication of metformin therapy that needs timely identification and management.
- Very high lactic acid can lead to an osmolar gap. However, common causes of an osmolar-gap like ethanol ingestion and toxins are to be ruled out.
- Clinicians should counsel patients to seek medical advice when feeling sick while on metformin therapy.
Metformin is an oral hypoglycemic agent that works by inhibiting hepatic gluconeogenesis. It is globally used as a first-line type 2 diabetes treatment, perhaps due to its effect on glucose reduction, weight neutrality, a favorable risk profile, and the low risk of hypoglycemia.[3–5] Despite being effective and generally safe, metformin-associated lactic acidosis (MALA), a dreadful rare side effect, has always been a clinicians’ concern, especially when dealing with patients suffering from liver or kidney disease. MALA is a high anion-gap (AG) acidosis that is generally thought to be not associated with osmolar-gap (OG). Here we present a case of MALA associated with an OG highlighting this seemingly unusual association; we discuss the possible mechanism, management, and argue that OG maybe not an infrequent occurrence in patients with MALA.
2 Case description
We present the case of a 45-year-old gentleman, known diabetic for 6 years on metformin 1 g, twice a day, with reasonable control (hemoglobin A1c 6.4%). He was admitted to our emergency feeling unwell with 2 days’ history of vomiting and watery diarrhea, also associated crampy periumbilical pain. He denied a history of similar complaints in his companions, no change in his dietary habits preceding symptoms’ onset. He drinks alcohol occasionally; the last drink was 6 months before the presentation—no illicit drug use history. The initial vital signs were normal. Soon later, he became tachycardic with heart rate reaching 120 bpm, blood pressure 127/70 mmHg, and a normal temperature. He looked dehydrated; otherwise, his examination was unremarkable.
Laboratory workup was significant for initially low glucose 2.5 mmol/L (3.3–5.5 mmol/L), high serum creatinine 632 μmol/L (62–106 umol/L), and high blood urea nitrogen of 21 mmol/L (2.8–8 mmol/L). Serum electrolytes were as follows: potassium (K+) 6.3 mmol/L (3.5–5.1 mmol/L), sodium (NA) 144 mmol/L (135–145mmol/L), bicarbonate (HCO3) 5.8 mmol/L (23–29 mmol/L), and serum chloride 99 mmol/L (99–107 mmol/L). Serum aminotransferases were normal (ALT 31 U/L, AST 27 U/L). He had significant high AG metabolic acidosis with PH of 6.8 (7.35–7.45) and AG of 40, lactic acid (LA) strikingly high reaching up to 24 mmol/L (0.5–2.2 mmol/L). With LA of 19 mmol/L, his OG measured 20 with serum osmolarity of 340 mmol/kg (275–295 mmol/kg). Toxicology screening, including serum ethanol, acetaminophen, salicylate, and urine for oxalate crystal, was negative.
Acidosis failed to respond to initial fluid hydration, including intravenous bicarbonate. Thus, the patient underwent 2 sessions of sustained low-efficiency hemodialysis (HD). After HD, his electrolyte disturbances improved, and intravenous fluid hydration continued. Acute kidney injury (AKI) workup, including antinuclear antibodies (ANA), antinuclear cytoplasmic antibodies, creatinine kinase level, and sepsis workup were unremarkable. Starting day 3, the patient was in a polyuric phase, suggestive of acute tubular necrosis (ATN), producing between 3 and 6 L per day, and his serum creatinine was decreasing. He was discharged after 8 days of hospitalization in good condition with a serum creatinine of 140 μmol/L (62–106 μmol/L). Figure 1 shows serum creatinine trend during the hospitalization, Figure 2 depicts serum lactic acid clearance during hospitalization.
Our patient had an AKI with significant lactic acidosis and an OG. Given the significant level of lactic acid, MALA was the likely diagnosis. Our patient was on metformin for a long time, and he did not attempt an overdose; hence, we think that MALA was likely precipitated by dehydration leading to prerenal insult and AKI. Eventually, his prerenal insult led to acute tubular necrosis, as evident by the polyuric phase the patient exhibited on day three.
Metformin, an oral hypoglycemic agent, is considered the first-line therapy for type II diabetes mellitus.[2,6] Metformin is generally effective and safe. The associated adverse event (AE) rate is estimated to be around 20% to 30%, with the majority of these AE in the form of gastrointestinal related symptoms, such as abdominal discomfort and nausea.
In extreme cases, metformin can rarely lead to lactate build-up and, eventually, acidosis, a condition known as Biguanide or metformin-associated lactic acidosis (MALA). This condition (MALA) was first described in 1977, and since then, studies have emerged exploring this rare entity. The available data suggest that the pooled incidence averages around 3 to 10 per 100,000 person-years. Despite being rare, MALA is associated with significant morbidity and mortality that is as high as 61%. MALA presentation may vary with the presence of gastrointestinal symptoms, hemodynamic compromise, tachypnea, and abnormal mentation. This atypical nature may hinder or delay proper diagnosis and care.
MALA is postulated to be due to the effect of metformin on transitioning the metabolism of glucose from aerobic to anaerobic, which leads to increased lactate levels[12,13]; however, in a therapeutic dose, this is likely to achieve a therapeutic effect without inducing relevant clinical acidosis. Therefore, MALA usually develops in the presence of conditions altering lactate metabolism, either increasing lactate production (metformin overdose), or impairing its clearance (hypo-perfusion, acute infection, renal or hepatic insufficiency). The term MALA has been debated and questioned by Lalau et al with the suggestion of differentiating between; metformin-unrelated lactic acidosis (MULA), metformin-induced lactic acidosis (MILA) and metformin-associated lactic acidosis, the details of differences and definitions of each condition are beyond the scope of our review. However, it is worthy to note that the author postulated that majority of the cases of MALA are MULA.
Our case was interesting, not only because of the presence of the rare MALA entity, but also the additional finding of an OG. We wanted to explore the frequency of OG in patients with MALA. We systematically searched PubMed without limitations using the terms; (((osmolar gap) OR (increased Osmolarity)) OR (osmolal gap)) AND ((((MALA) OR (metformin-associated lactic acidosis)) OR (metformin toxicity)) OR (metformin acidosis)). Our search retrieved only 3 citations and they were all not relevant to our review question. It seems that the authors did not highlight this relationship in their cases or studies. A search in google scholar and free text on google retrieved 10 relevant citations[14–23] out of which 9 cases described cases of MALA in which OG was present. It was highlighted by the authors in 4 cases discussing an extensive workup to rule out causes of the OG and even attempts to start Fomepizole till ruling out ethylene glycol toxicity. The highest OG reported was 89 mOsm/L. Table 1 shows the results of the literature review). Spiller et al. reviewed the Toxic Exposure Surveillance System (TESS) looking for metformin toxicity, in 9 fatalities related to metformin toxicity, 4 cases were found to have an elevated OG, and in all instances, ethylene glycol and methanol were negative.
We reviewed the relationship between lactic acidosis and OG. We found an interesting study by Schelling et al exploring whether an elevated OG is specific to alcohol intoxication. In an arm including 23 patients with lactic acidosis, the OG was found to be high with a mean of 17 mOsm/L. The authors concluded that the OG is not specific for alcohol intoxication and that lactic acidosis can lead to an OG. However, the exact mechanism remains uncertain.
In the presence of an OG, the diagnosis of MALA may be challenging and even overlooked. However, clinicians must be aware that significant lactic acidosis can lead to an OG. We have highlighted in our review that severe cases of MALA specifically presented with an OG. Whether the OG in these cases is purely related to lactic acid build-up or due to metformin remains unclear; additionally, the prevalence of OG in MALA is unknown as not all cases, or studies reported OG measurements. We suggest when MALA is suspected in the event of an OG, that a quick workup to exclude other causes of an OG be performed, but that should not delay timely identification and treatment of MALA.
Our case is compelling because it is the first case highlighting the MALA association with an OG and discussing it in-depth with a systematic scoping search. Physicians should be aware of this possible relationship. Although rare, patients should be counseled on this side effect and asked to report to physicians when feeling sick.
MALA is a rare side effect of metformin. Nevertheless, associated with significant morbidity and mortality; thus, it should be diagnosed and treated promptly. High lactic acid and MALA can lead to an OG. After ruling out the common causes of an OG, the presence of an OG should not hinder a timely diagnosis and management of MALA. This relationship should be further studied. Patients on metformin therapy should be counseled about the risk of MALA and advised to seek medical advice when feeling sick.
The authors thank Qatar National Library for funding the publication of this article. The authors acknowledge the efforts of the treating medical team, especially Dr. AL Mehdi Alrayyes. Dr. Zahid and Dr. Karim Bayomi.
∗MFHM and MN contributed equally to this paper. MN and MFHM conceived the idea and wrote the initial draft. MN and MFHM constructed the table and figures. MFHM reviewed and updated the manuscript and supervised the work. All authors reviewed the final manuscript and approved it for publication.
. Foretz M, Guigas B, Bertrand L, et al. Metformin: from mechanisms of action to therapies. Cell Metab 2014;20:953–66.
. Schlender L, Martinez YV, Adeniji C, et al. Efficacy and safety of metformin in the management of type 2 diabetes mellitus in older adults: a systematic review for the development of recommendations to reduce potentially inappropriate prescribing. BMC Geriatr [Internet] 2017;17: (suppl 1): 227.
. Kuan IHS, Savage RL, Duffull SB, et al. The association between metformin therapy and lactic acidosis. Drug Saf 2019;42:1449–69.
. Turner R. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–65.
. Golay A. Metformin and body weight. Int J Obes 2008;32:61–72.
. Bray GA, Edelstein SL, Crandall JP, et al. Long-term safety, tolerability, and weight loss associated with metformin in the diabetes prevention program outcomes study. Diabetes Care 2012;35:731–7.
. Edwards CMB, Barton MA, Snook J, et al. Metformin-associated lactic acidosis in a patient with liver disease. QJM An Int J Med [Internet] 2003;96:315–6.
. Phillips PJ, Thomas DW, Harding PE. Biguanides and lactic acidosis. Br Med J 1977;1:234.
. Lalau J-D, Kajbaf F, Protti A, et al. Metformin-associated lactic acidosis (MALA): moving towards a new paradigm. Diabetes 2017;19:1502–12.
. Kajbaf F, Lalau JD. Mortality rate in so-called “metformin-associated lactic acidosis”: A review of the data since the 1960 s. Pharmacoepidemiol Drug Saf 2014;23:1123–7.
. Metformin and Fatal Lactic Acidosis [Internet]. [cited 2020 Feb 19]. Available from: https://www.medsafe.govt.nz/profs/PUarticles/5.htm
. Arieff AI, Park R, Leach WJ, et al. Pathophysiology of experimental lactic acidosis in dogs. Am J Physiol 1980;8:135–42.
. Radziuk J, Zhang Z, Wiernsperger N, et al. Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver. Diabetes 1997;46:1406–13.
. Amin R, Walter R, Bunin J. Metformin associated lactic acidosis mimicking ethylene glycol ingestionin in an alcoholic patient. Chest [Internet] 2013;144:352A.
. Parekh N, Soi S. 239 Osmolar gap
metabolic acidosis associated with lactic acidosis in patient taking metformin: a case report. Am J Kidney Dis [Internet] B76;57:
. Suchard JR, Grotsky TA. Fatal metformin overdose presenting with progressive hyperglycemia. West J Emerg Med [Internet] 2008;9:160–4.
. Umeda T, Minami T, Bartolomei K, et al. Metformin-associated lactic acidosis: a case report. Drug Saf 2018;5:8.
. Abu-Hishmeh M, Martin A, Morton R, Murthy S, Gnanasekaran I. Combined Metformin Associated Lactic Acidosis and Starvation Ketoacidosis with Very High Osmolal Gap. In: American Thoracic Society International Conference Meetings Abstracts American Thoracic Society International Conference Meetings Abstracts. American Thoracic Society; 2019. p. A1735–A1735.
. Al-khasawneh K, White P. Lactic acidosis secondary to metformin overdose. Chest 2006;130:337S.
. Raoof S. Metformin Associated Lactic Acidosis. In: C41 Critical Care Case Reports: Toxicology And Poisonings [Internet]. American Thoracic Society; 2019 [cited 2020 Feb 20]. p. A4805–A4805. Available from: https://www.atsjournals.org/doi/10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A4805
. Yayar Ö, Şahin M, Eser B, et al. Metformin associated lactic acidosis resulted in cardiopulmonary arrest: a rare case. J Heal Sci Med [Internet] 2018;1:106–9.
. Lam N, Sekhon G, House AA. Metformin-Associated Lactic Acidosis following Intentional Overdose Successfully Treated with Tris-Hydroxymethyl Aminomethane and Renal Replacement Therapy. Case Reports Nephrol [Internet]. 2012 [cited 2020 Sep 15];2012:1–5. Available from: https://pubmed.ncbi.nlm.nih.gov/24533205/
. Spiller HA, Quadrani DA. Toxic effects from metformin exposure. Ann Pharmacother [Internet] 2004;38:776–80.
. Schelling JR, Howard RL, Winter SD, et al. Increased osmolal gap in alcoholic ketoacidosis and lactic acidosis. Ann Intern Med [Internet] 580;113: